Search

Your search keyword '"Friedrichs, Kay"' showing total 93 results
Start Over Author "Friedrichs, Kay"
93 results on '"Friedrichs, Kay"'

1. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept

Author

Pfob, André, Cai, Lie, Schneeweiss, Andreas, Rauch, Geraldine, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Degenhardt, Tom, Rom, Joachim, Rody, Achim, van Mackelenbergh, Marion, Banys-Paluchowski, Maggie, Große, Regina, Reinisch, Mattea, Karsten, Maria Margarete, Sidey-Gibbons, Chris, Wallwiener, Markus, Golatta, Michael, and Heil, Joerg

Published
2024
Full Text
View/download PDF

2. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment—A New Concept

Author

Pfob, André, Cai, Lie, Schneeweiss, Andreas, Rauch, Geraldine, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Degenhardt, Tom, Rom, Joachim, Rody, Achim, van Mackelenbergh, Marion, Banys-Paluchowski, Maggie, Große, Regina, Reinisch, Mattea, Karsten, Maria Margarete, Sidey-Gibbons, Chris, Wallwiener, Markus, Golatta, Michael, and Heil, Joerg

Published
2024
Full Text
View/download PDF

3. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment—A New Concept

Author

Pfob, André, primary, Cai, Lie, additional, Schneeweiss, Andreas, additional, Rauch, Geraldine, additional, Thomas, Bettina, additional, Schaefgen, Benedikt, additional, Kuemmel, Sherko, additional, Reimer, Toralf, additional, Hahn, Markus, additional, Thill, Marc, additional, Blohmer, Jens-Uwe, additional, Hackmann, John, additional, Malter, Wolfram, additional, Bekes, Inga, additional, Friedrichs, Kay, additional, Wojcinski, Sebastian, additional, Joos, Sylvie, additional, Paepke, Stefan, additional, Degenhardt, Tom, additional, Rom, Joachim, additional, Rody, Achim, additional, van Mackelenbergh, Marion, additional, Banys-Paluchowski, Maggie, additional, Große, Regina, additional, Reinisch, Mattea, additional, Karsten, Maria Margarete, additional, Sidey-Gibbons, Chris, additional, Wallwiener, Markus, additional, Golatta, Michael, additional, and Heil, Joerg, additional

Published
2023
Full Text
View/download PDF

4. Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice

Author

Danaei, Mahmoud, Stickeler, Elmar, Sarlos, Dimitri, Prové, Annemie, Pagani, Olivia, Berclaz, Gilles, Taffurelli, Mario, Cretella, Elisabetta, Verhoeven, Didier, Denk, Andreas, Carly, Birgit, Ballardini, Bettina, van Riet, Yvonne, Kimmig, Rainer, Reinisch, Mattea, Angiolini, Catia, Möbus, Volker, Emons, Gunter, Friedrichs, Kay, Schneeweiss, Andreas, Tinterri, Corrado, Egle, Daniel, Staelens, Gracienne, Kiechle, Marion, Harbeck, Nadia, Corsi, Fabio, Menghini, Lorenzo, Lombardi, Augusto, Fortunato, Lucio, Bortul, Marina, Huober, Jens, Badbanchi, Farzaneh, Tausch, Christoph, Garcia-Etienne, Carlos A., Mansel, Robert E., Tomatis, Mariano, Heil, Joerg, Biganzoli, Laura, Ferrari, Alberta, Marotti, Lorenza, Sgarella, Adele, and Ponti, Antonio

Published
2019
Full Text
View/download PDF

5. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept

Author

Pfob, André, primary, Cai, Lie, additional, Schneeweiss, Andreas, additional, Rauch, Geraldine, additional, Thomas, Bettina, additional, Schaefgen, Benedikt, additional, Kuemmel, Sherko, additional, Reimer, Toralf, additional, Hahn, Markus, additional, Thill, Marc, additional, Blohmer, Jens-Uwe, additional, Hackmann, John, additional, Malter, Wolfram, additional, Bekes, Inga, additional, Friedrichs, Kay, additional, Wojcinski, Sebastian, additional, Joos, Sylvie, additional, Paepke, Stefan, additional, Degenhardt, Tom, additional, Rom, Joachim, additional, Rody, Achim, additional, van Mackelenbergh, Marion, additional, Banys-Paluchowski, Maggie, additional, Große, Regina, additional, Reinisch, Mattea, additional, Karsten, Maria Margarete, additional, Sidey-Gibbons, Chris, additional, Wallwiener, Markus, additional, Golatta, Michael, additional, and Heil, Joerg, additional

Published
2023
Full Text
View/download PDF

6. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03

Author

Heil, Joerg, Pfob, André, Sinn, Hans-Peter, Rauch, Geraldine, Bach, Paul, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Ditsch, Nina, Rody, Achim, Große, Regina, van Mackelenbergh, Marion, Reinisch, Mattea, Karsten, Maria, and Golatta, Michael

Published
2020
Full Text
View/download PDF

7. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Author

Koroveshi, Dhurata, Bouzid, Kamel, Casalnuovo, Monica, Cascallar, Diana, Korbenfeld, Ernesto Pablo, Bastick, Patricia, Beith, Jane, Colosimo, Maree, Friedlander, Michael, Ganju, Vinod, Green, Michael, Patterson, Kevin, Redfern, Andrew, Richardson, Gary, Ceric, Timur, Gordana, Kecman, Beato, Carlos Augusto, Ferrari, Marcela, Hegg, Roberto, Helena, Vanessa, Ismael, Gustavo Fernando, Lessa, Alvaro Edson, Mano, Max, Morelle, Alessandra, Nogueira, Jose Alberto, Timcheva, Konstanta, Tomova, Antoaneta, Tsakova, Maya, Zlatareva-Petrova, Ani, Asselah, Jamil, Assi, Hazem, Brezden-Masley, Christine, Chia, Stephen, Freedman, Ori, Harb, Mohammed, Joy, Anil Abraham, Kulkarni, Swati, Prady, Catherine, Gaete, Alejandro Andres Acevedo, Matamala, Luis, Torres, Roberto, Yanez, Eduardo, Franco, Sandra, Urrego, Marcela, Gugić, Damir, Vrbanec, Damir, Melichar, Bohuslav, Prausová, Jana, Vyzula, Rostislav, Pilarte, Rafael Gutierrez, León, María Isabel, Muñoz, Rene, Ramos, Glenda, Azeem, Hamdy Abdel, Aziz, Amr Abdel, El Zawahry, Heba, Osegueda, Finlander Rosales, Alexandre, Jerome, Artignan, Xavier, Barletta, Hugues, Beguier, Emmanuel, Berdah, Jean-François, Marty, Chantal Bernard, Bollet, Marc, Bourgeois, Hugues, Bressac, Claude, Burki, Franck, Campone, Mario, Coeffic, David, Cojocarasu, Oana Zveltlana, Dagada, Corinne, Dalenc, Florence, Del Piano, Francesco, Desauw, Christophe, Desmoulins, Isabelle, Dohollou, Nadine, Egreteau, Joelle, Ferrero, Jean-Marc, Foa, Cyril, Garidi, Reda, Gasnault, Laurent, Gligorov, Joseph, Guardiola, Emmanuel, Hamizi, Salima, Jarcau, Rosana, Jacquin, Jean-Philippe, Jaubert, Dominique, Jolimoy, Geneviève, Mineur, Hortense Laharie, Largillier, Remy, Leduc, Bernard, Martin, Philippe, Melis, Adrien, Monge, Jeremy, Moullet, Isabelle, Mousseau, Mireille, Nguyen, Suzanne, Orfeuvre, Hubert, Petit, Thierry, Pivot, Xavier, Priou, Frank, Bach, Isabelle Sillet, Simon, Helene, Stefani, Laetitia, Uwer, Lionel, Youssef, Ali, Aktas, Bahriye, von der Assen, Albert, Augustin, Doris, Balser, Christina, Bauer, Lelia-Eveline, Bechtner, Christina, Beyer, Greta, Brucker, Cosima, Bückner, Ute, Busch, Steffi, Christensen, Bernd, Deryal, Mustafa, Farrokh, Andre, Faust, Elke, Friedrichs, Kay, Graf, Heiko, Griesshammer, Martin, Grischke, Eva-Maria, Hänle, Claudia, Heider, Andrea, Henschen, Stephan, Hesse, Tobias, Jackisch, Christian, Kisro, Jens, Köhler, Andreas, Kuemmel, Sherko, Lampe, Dieter, Lantzsch, Tilmann, Latos, Kunibert, Lex, Benno, Liedtke, Cornelia, Luedders, Doerte, Maintz, Christoph, Müller, Volkmar, Overkamp, Friedrich, Park-Simon, Tjoung-won, Paul, Marion, Prechtl, Anita, Ringsdorf, Uta, Runnebaum, Ingo, Ruth, Sylvia, Salat, Christoph, Scheffen, Iris, Schilling, Jörg, Schmatloch, Sabine, Schmidt, Marcus, Schneeweiss, Andreas, Schrader, Iris, Seipelt, Gernot, Simon, Elke, Stefek, Andrea, Stickeler, Elmar, Thill, Marc, Tio, Joke, Tuczek, Anna, Warm, Mathias, Weigel, Michael, Wischnik, Arthur, Wojcinski, Sebastian, Ziegler-Löhr, Katja, Aravantinos, Gerasimos, Ardavanis, Alexandros, Fountzilas, George, Gogas, Helen, Kakolyris, Stylianos, Mavroudis, Dimitris, Papadimitriou, Christos, Papandreou, Christos, Papazisis, Konstantinos, Castro, Hugo, Hernandez-Monroy, Cesar Estuardo, Ngan, Roger, Yeo, Winnie, Bittner, Nora, Boer, Katalin, Csejtei, Andras, Horvath, Zsolt, Kocsis, Judit, Mangel, László Csaba, Mezei, Klara, Nagy, Zsuzsanna, Szanto, Janos, Atmakusuma, Djumhana, Fadjari, Heri, Kurnianda, Djohan, Prayogo, Nugroho, Tanggo, Eddie Herman, Coate, Linda, Hennessy, Bryan, Kelly, Cathy, Martin, Michael, Nasim, Saira, O'Connor, Miriam, Aieta, Michele, Allegrini, Giacomo, Amadori, Dino, Bidoli, Paolo, Biti, Giampaolo, Bordonaro, Roberto, Bottini, Alberto, Carterni, Giacomo, Cavanna, Luigi, Cazzaniga, Marina, Cognetti, Francesco, Contu, Antonio, Cruciani, Giorgio, Donadio, Michela, Falcone, Alfredo, Farci, Daniele, Forcignanò, R. Chiara, Frassoldati, Antonio, Gaion, Fernando, Gamucci, Teresa, Giotta, Francesco, de Laurentiis, Michele, Livi, Lorenzo, Lorusso, Vito, Maiello, Evaristo, Marchetti, Paolo, Mariani, Gabriella, Mion, Marta, Moscetti, Luca, Musolino, Antonino, Pazzola, Antonio, Pedrazzoli, Paolo, Pigi, Andrea, de Placido, Sabino, Caremoli, Elena Rota, Santoro, Armando, Tienghi, Amelia, Ahn, Jin-Seok, Jung, Kyung Hae, Lee, Keun Seok, Lee, Soo Hyeon, Seo, Jae Hong, Sohn, Joo-Hyuk, Cesas, Alvydas, Juozaityte, Elona, Cheah, Nellie Lay Chin, Chong, Flora Li Tze, Devi, Beena C.R., Phua, Vincent, Teoh, Darren, Ching, Lee Wei, Yusof, Mastura, Corona, Jorge, Dominguez, Adriana, Mendoza, René Lazaro González, Hernandez, Carlos Alberto, Ramiro, Alejandro Juarez, Santos, Juan Matos, Espinosa, Paola Morales, Villarreal Garza, Cynthia Mayte, Errihani, Hassan, Bakker, Sandra, van den Berkmortel, Franchette, Blaisse, R.J.B., Huinink, Daan ten Bokkel, van den Bosch, J., Braun, J.J., Dercksen, M.W., Droogendijk, Helga, Erdkamp, Frans, Haringhuizen, Annebeth, de Jongh, F.E., Kok, T.C., Los, Maartje, Madretsma, Stanley, Terwogt, Jetske M. Meerum, van der Padt, Annemieke, van Rossum-Schornagel, Quirine Clementine, Smilde, T.J., de Valk, Bart, van der Velden, Annette, van Warmerdam, Laurence, van de Wouw, A.J., North, Richard, Kersten, Christian, Mjaaland, Ingvild, Wist, Erik, Aziz, Zeba, Masood, Nehal, Rashid, Kamran, Shah, Mazhar, Alcedo, Juan Carlos, Aleman, Diana, Neciosup, Silvia, Reategui, Rocio, Valdiviezo, Natalia, Vera, Luis, Fernando, Gracieux, Roque, Fernando, Strebel, Heinrik Martin, Krzemieniecki, Krzysztof, Litwiniuk, Maria, Mruk, Andrzej, Pienkowski, Tadeusz, Sawrycki, Piotr, Slomian, Grzegorz, Tomczak, Piotr, Afonso, Noemia, Cardoso, Fátima, Damasceno, Margarida, Nave, Monica, Badulescu, Florinel, Ciule, Larisa, Curescu, Stefan, Eniu, Alexandru, Filip, Dumitru, Grecea, Daniela, Jinga, Dan-Corneliu, Lungulescu, Dan, Oprean, Cristina Marinela, Stanculeanu, Dana Lucia, Turdean, Maria, Dvornichenko, Viktoria, Emelyanov, Sergey, Lichinitser, Mikhail, Manikhas, Alexey, Sakaeva, Dina, Shirinkin, Vadim, Stroyakovskiy, Daniil, Abulkhair, Omalkhair, Zekri, Jamal, Filipovic, Sladjana, Kovcin, Vladimir, Nedovic, Jasmina, Pesic, Jasna, Vasovic, Suzana, Ng, Raymond, Bystricky, Branislav, Leskova, Jaroslava, Mardiak, Jozef, Mišurová, Etela, Wagnerova, Maria, Takač, Iztok, Demetriou, Georgia Savva, Dreosti, Lydia, Govender, Poovandren, Jordaan, Johannes Petrus, Veersamy, Petrosian, Romero, Jose Luis Alonso, Lopez, Norberto Batista, Arias, Carmen Cañabate, Chacon, Jose, Aramburo, Antonio Fernandez, Morales, Luis Antonio Fernandez, Garcia, Mirta, Estevez, Laura Garcia, Garcia-Palomo Perez, Andres, Garcia Saenz, Jose Angel, Garcia Sanchis, Laura, Cubells, Laia Garrigos, Cortijo, Lucia Gonzalez, Santiago, Santiago Gonzalez, De Aranguiz, Blanca Hernando Fernandez, Mañas, José Juan Illarramendi, Gallego, Pedro Jimenez, Cussac, Antonio Llombart, Ferrandiz, Cristina Llorca, Garrido, Maria Lomas, Alvarez, Pilar Lopez, Vega, Jose Manuel Lopez, Del Prado, Purificacion Martinez, Jañez, Noelia Martinez, Murillo, Serafin Morales, Rosales, Adolfo Murias, Jaso, Laura Murillo, Fernandez, Ignacio Pelaez, Martorell, Antonia Perello, Carrion, Ramon Perez, Simon, Sonia Pernas, Alcibar, Arrate Plazaola, Lorenzo, Jose Ponce, Garcia, Vanesa Quiroga, Asensio, Teresa Ramon y Cajal, Maicas, Maria Dolores Torregrosa, Villanueva Silva, Maria Jose, Killander, Fredrika, Svensson, Jan Henry, Fehr, Mathias, Hauser, Nik, Müller, Andreas, Pagani, Olivia, Passmann-Kegel, Heike, Popescu, Razvan, Rabaglio, Manuela, Rauch, Daniel, Schlatter, Christina, Zaman, Khalil, Chang, Tsai-Wang, Huang, Chiun-Sheng, Wang, Hwei-Chung, Yu, Jyh-Cherng, Bandidwattanawong, Chanyoot, Maneechavakajorn, Jedzada, Seetalarom, Kasan, Dejthevaporn, Thitiya (Sirisinha), Somwangprasert, Areewan, Vongsaisuwon, Mawin, Akbulut, Hakan, Altundag, Kadri, Arican, Ali, Bozcuk, Hakan, Eralp, Yesim, Idris, Mohamed, Isikdogan, Abdurrahman, Senol, Coskun Hasan, Sevinc, Alper, Uygun, Kazim, Yucel, Eftal, Yucel, Idris, Yumuk, Fulden, Shparyk, Yaroslav, Voitko, Nataliia, Jaloudi, Mohammed, Adams, Jocelyn, Agrawal, Rajiv, Ahmed, Samreen, Alhasso, Abdulla, Allerton, Rozenn, Anwar, Suhail, Archer, Caroline, Ashford, Richard, Barraclough, Lisa, Bertelli, Gianfilippo, Bishop, Jill, Branson, Tony, Butt, Mohammed, Chakrabarti, Amit, Chakraborti, Prabir, Churn, Mark, Crowley, Clare, Davis, Ruth, Dhadda, Amandeep, Eldeeb, Hany, Fraser, Judith, Hall, Julia, Hickish, Tamas, Hogg, Martin, Howe, Theresa, Joffe, Jonathan, Kelleher, Muireann, Kelly, Stephen, Kendall, Anne, Kristeleit, Hartmut, Lumsden, Graeme, Macmillan, Craig, MacPherson, Iain, Malik, Zafar, Mithal, Natasha, Neal, Anthony, Panwar, Udaiveer, Proctor, Andrew, Proctor, Steven John, Raj, Sanjay, Rehman, Shazza, Sandri, Ines, Scatchard, Kate, Sherwin, Elizabeth, Sims, Eliot, Singer, Julian, Smith, Sarah, Tahir, Saad, Taylor, Wendy, Tsalic, Medy, Verrill, Mark, Wardley, Andrew, Waters, Simon, Wheatley, Duncan, Wright, Kathryn, Yuille, Frances, Alonso, Isabel, Artagaveytia, Nora, Rodriguez, Robinson, Arbona, Esther, Garcia, Yuraima, Lion, Lorena, Marcano, Dalila, Van Thuan, Tran, Gligorov, J., Ataseven, B., Verrill, M., De Laurentiis, M., Jung, K.H., Azim, H.A., Al-Sakaff, N., Lauer, S., Shing, M., and Pivot, X.

Published
2017
Full Text
View/download PDF

9. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery

Author

Pfob, André, primary, Sidey-Gibbons, Chris, additional, Rauch, Geraldine, additional, Thomas, Bettina, additional, Schaefgen, Benedikt, additional, Kuemmel, Sherko, additional, Reimer, Toralf, additional, Hahn, Markus, additional, Thill, Marc, additional, Blohmer, Jens-Uwe, additional, Hackmann, John, additional, Malter, Wolfram, additional, Bekes, Inga, additional, Friedrichs, Kay, additional, Wojcinski, Sebastian, additional, Joos, Sylvie, additional, Paepke, Stefan, additional, Degenhardt, Tom, additional, Rom, Joachim, additional, Rody, Achim, additional, van Mackelenbergh, Marion, additional, Banys-Paluchowski, Maggie, additional, Große, Regina, additional, Reinisch, Mattea, additional, Karsten, Maria, additional, Golatta, Michael, additional, and Heil, Joerg, additional

Published
2022
Full Text
View/download PDF

10. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03

Author

Heil, Joerg, Pfob, Andre, Sinn, Hans-Peter, Rauch, Geraldine, Bach, Paul, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Ditsch, Nina, Rody, Achim, Grosse, Regina, van Mackelenbergh, Marion, Reinisch, Mattea, Karsten, Maria, Golatta, Michael, Heil, Joerg, Pfob, Andre, Sinn, Hans-Peter, Rauch, Geraldine, Bach, Paul, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Ditsch, Nina, Rody, Achim, Grosse, Regina, van Mackelenbergh, Marion, Reinisch, Mattea, Karsten, Maria, and Golatta, Michael

Abstract

Objective:We evaluated the ability of minimally invasive, image-guided vacuum-assisted biopsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B).Summary Background Data:Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in up to 80% of women with breast cancer. In such cases, breast surgery, the gold standard for confirming pCR-B, may be considered overtreatment.Methods:This multicenter, prospective trial enrolled 452 women presenting with initial stage 1-3 breast cancer of all biological subtypes. Fifty-four women dropped out; 398 were included in the full analysis. All participants had an imaging-confirmed partial or complete response to NST and underwent study-specific image-guided VAB before guideline-adherent breast surgery. The primary endpoint was the false-negative rate (FNR) of VAB-confirmed pCR-B.Results:Image-guided VAB alone did not detect surgically confirmed residual tumor in 37 of 208 women [FNR, 17.8%; 95% confidence interval (CI), 12.8-23.7%]. Of these 37 women, 12 (32.4%) had residual DCIS only, 20 (54.1%) had minimal residual tumor (<5mm), and 19 of 25 (76.0%) exhibited invasive cancer cellularity of 10%. In 19 of the 37 cases (51.4%), the false-negative result was potentially avoidable. Exploratory analysis showed that performing VAB with the largest needle by volume (7-gauge) resulted in no false-negative results and that combining imaging and image-guided VAB into a single diagnostic test lowered the FNR to 6.2% (95% CI, 3.4%-10.5%).Conclusions:Image-guided VAB missed residual disease more often than expected. Refinements in procedure and patient selection seem possible and necessary before omitting breast surgery.

Published
2022

11. Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery

Author

Pfob, Andre, Sidey-Gibbons, Chris, Rauch, Geraldine, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Degenhardt, Tom, Rom, Joachim, Rody, Achim, van Mackelenbergh, Marion, Banys-Paluchowski, Maggie, Grosse, Regina, Reinisch, Mattea, Karsten, Maria, Golatta, Michael, Heil, Joerg, Pfob, Andre, Sidey-Gibbons, Chris, Rauch, Geraldine, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, Degenhardt, Tom, Rom, Joachim, Rody, Achim, van Mackelenbergh, Marion, Banys-Paluchowski, Maggie, Grosse, Regina, Reinisch, Mattea, Karsten, Maria, Golatta, Michael, and Heil, Joerg

Abstract

PURPOSE Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in 40%-70% of women with breast cancer. These patients may not need surgery as all local tumor has already been eradicated by NST. However, nonsurgical approaches, including imaging or vacuum-assisted biopsy (VAB), were not able to accurately identify patients without residual cancer in the breast or axilla. We evaluated the feasibility of a machine learning algorithm (intelligent VAB) to identify exceptional responders to NST. METHODS We trained, tested, and validated a machine learning algorithm using patient, imaging, tumor, and VAB variables to detect residual cancer after NST (ypT+ or in situ or ypN+) before surgery. We used data from 318 women with cT1-3, cN0 or +, human epidermal growth factor receptor 2-positive, triple-negative, or high-proliferative Luminal B-like breast cancer who underwent VAB before surgery (ClinicalTrials.gov identifier: , RESPONDER trial). We used 10-fold cross-validation to train and test the algorithm, which was then externally validated using data of an independent trial (ClinicalTrials.gov identifier: ). We compared findings with the histopathologic evaluation of the surgical specimen. We considered false-negative rate (FNR) and specificity to be the main outcomes. RESULTS In the development set (n = 318) and external validation set (n = 45), the intelligent VAB showed an FNR of 0.0%-5.2%, a specificity of 37.5%-40.0%, and an area under the receiver operating characteristic curve of 0.91-0.92 to detect residual cancer (ypT+ or in situ or ypN+) after NST. Spiegelhalter's Z confirmed a well-calibrated model (z score -0.746, P = .228). FNR of the intelligent VAB was lower compared with imaging after NST, VAB alone, or combinations of both. CONCLUSION An intelligent VAB algorithm can reliably exclude residual cancer after NST. The omission of breast and axillary surgery for these exceptional responders may be evaluated in future trials.

Published
2022

13. Cancer Cell Motility Through Unjamming Impacts Metastatic Risk

Author

Käs, Josef, primary, Lippoldt, Jürgen, additional, Grosser, Steffen, additional, Tschodu, Dimitrij, additional, Renner, Frédéric, additional, Kubitschke, Hans, additional, Poßögel, Anne-Kathrin, additional, Wegscheider, Anne-Sophie, additional, Ulm, Bernhard, additional, Friedrichs, Kay, additional, Lindner, Christoph, additional, Wolf, Benjamin, additional, Höckel, Michael, additional, Aktas, Bahriye, additional, Gottheil, Pablo, additional, and Niendorf, Axel, additional

Published
2022
Full Text
View/download PDF

15. Abstract PD7-02: Intelligent vacuum-assisted breast biopsy to identify breast cancer patients with pathologic complete response after neoadjuvant systemic treatment for omission of breast and axillary surgery

Author

Pfob, André, primary, Sidey-Gibbons, Chris, additional, Rauch, Geraldine, additional, Thomas, Bettina, additional, Schaefgen, Benedikt, additional, Kuemmel, Sherko, additional, Reimer, Toralf, additional, Hahn, Markus, additional, Thill, Marc, additional, Blohmer, Jens-Uwe, additional, Hackmann, John, additional, Malter, Wolfram, additional, Bekes, Inga, additional, Friedrichs, Kay, additional, Wojcinski, Sebastian, additional, Joos, Sylvie, additional, Paepke, Stefan, additional, Degenhardt, Tom, additional, Rom, Joachim, additional, Rody, Achim, additional, Große, Regina, additional, van Mackelenbergh, Marion, additional, Reinisch, Mattea, additional, Karsten, Maria, additional, Golatta, Michael, additional, and Heil, Joerg, additional

Published
2022
Full Text
View/download PDF

16. Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice

Author

Garcia-Etienne, Carlos A., Mansel, Robert E., Tomatis, Mariano, Heil, Joerg, Biganzoli, Laura, Ferrari, Alberta, Marotti, Lorenza, Sgarella, Adele, Ponti, Antonio, Danaei, Mahmoud, Stickeler, Elmar, Sarlos, Dimitri, Prové, Annemie, Pagani, Olivia, Berclaz, Gilles, Taffurelli, Mario, Cretella, Elisabetta, Verhoeven, Didier, Denk, Andreas, Carly, Birgit, Ballardini, Bettina, van Riet, Yvonne, Kimmig, Rainer, Reinisch, Mattea, Angiolini, Catia, Möbus, Volker, Emons, Gunter, Friedrichs, Kay, Schneeweiss, Andreas, Tinterri, Corrado, Egle, Daniel, Staelens, Gracienne, Kiechle, Marion, Harbeck, Nadia, Corsi, Fabio, Menghini, Lorenzo, Lombardi, Augusto, Fortunato, Lucio, Bortul, Marina, Huober, Jens, Badbanchi, Farzaneh, Tausch, Christoph, EUSOMA Working Group, EUSOMA Working Grp, Garcia-Etienne, C. A., Mansel, R. E., Tomatis, M., Heil, J., Biganzoli, L., Ferrari, A., Marotti, L., Sgarella, A., Ponti, A., Danaei, M., Stickeler, E., Sarlos, D., Prove, A., Pagani, O., Berclaz, G., Taffurelli, M., Cretella, E., Verhoeven, D., Denk, A., Carly, B., Ballardini, B., van Riet, Y., Kimmig, R., Reinisch, M., Angiolini, C., Mobus, V., Emons, G., Friedrichs, K., Schneeweiss, A., Tinterri, C., Egle, D., Staelens, G., Kiechle, M., Harbeck, N., Corsi, F., Menghini, L., Lombardi, A., Fortunato, L., Bortul, M., Huober, J., Badbanchi, F., and Tausch, C.

Subjects
axillary lymph node dissection, axillary dissection, axillary surgery, axillary lymphadenectomy, positive sentinel node, Z0011, surgery for breast cancer, Medizin, Practice Patterns, Axillary dissection, 0302 clinical medicine, Axillary lymph node dissection, Breast, 030212 general & internal medicine, Practice Patterns, Physicians', Stage (cooking), Surgical approach, Lymph Node, Axillary lymphadenectomy, General Medicine, Middle Aged, 3. Good health, Europe, medicine.anatomical_structure, Homogeneous, 030220 oncology & carcinogenesis, Female, Axillary surgery, Positive sentinel node, Surgery for breast cancer, Adult, Aged, Axilla, Breast Neoplasms, Humans, Lymph Node Excision, Lymph Nodes, Breast Neoplasm, Human, medicine.medical_specialty, 03 medical and health sciences, Breast cancer, medicine, Physicians', Breast conservation, business.industry, General surgery, Background data, Axillary Lymph Node Dissection, medicine.disease, Surgery, Human medicine, business
Abstract

Background: Data from recently published trials have provided practice-changing recommendations for the surgical approach to the axilla in breast cancer. Patients with T1-2 lesions, treated with breast conservation, who have not received neoadjuvant chemotherapy and have 1-2 positive sentinel nodes (Z0011-criteria) may avoid axillary lymph node dissection (ALND). We aim to describe the dissemination of this practice in Europe over an extended period of time. Methods: Our source of data was the eusomaDB, a central data warehouse of prospectively collected information of the European Society of Breast Cancer Specialists (EUSOMA). We identified cases fulfilling Z0011-criteria from 2005 to 2016 from 34 European breast centers and report trends in ALND. Data derived from Germany, Italy, Belgium, Switzerland, Austria, and Netherlands. Results: 6671 patients fulfilled Z0011-criteria. Rates of ALND showed a statistically significant decrease from 2010 (89%) to 2011 (73%), reaching 46% in 2016 (p < 0.001). After multivariable analysis, factors associated with higher probability of ALND were earlier year of surgery, younger age, increasing tumor size and grade, and being operated in Italy (p < 0.001). The minimum and maximal rates of ALND in the most recent two-year period (2015-2016) were 0% and 83% in two centers located in different countries (p < 0.001). Conclusion: Our study demonstrates, a decrease in rates of ALND that started after year 2010 through the end of the study period. Wide differences were observed among centers and countries indicating the need to spread unified clinical guidelines in Europe to allow for homogeneous evidence-based practice patterns. (C) 2019 Elsevier Ltd. All rights reserved.

Published
2019

18. CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer

Author

Marmé, Frederik, Werft, Wiebke, Walter, Anne, Keller, Sascha, Wang, Xiaoli, Benner, Axel, Burwinkel, Barbara, Sinn, Peter, Hug, Sarah, Sohn, Christof, Bretz, Niko, Moldenhauer, Gerhard, Rupp, Christian, Rupp, Anne-Kathleen, Biakhov, Mikhail Y., Bottini, Alberto, Friedrichs, Kay, Khailenko, V. A., Manikhas, Georgiy M., Ruiz, Amparo, Sánchez-Rovira, Pedro, Santoro, Armando, Segui, Miguel A., Villena, Carlos, Lichter, Peter, Kristiansen, Glen, Altevogt, Peter, and Schneeweiss, Andreas

Published
2012
Full Text
View/download PDF

19. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number...

Author

Heil, Joerg, Pfob, Andre, Sinn, Hans-Peter, Rauch, Geraldine, Bach, Paul, Thomas, Bettina, Schaefgen, Benedikt, Kuemmel, Sherko, Reimer, Toralf, Hahn, Markus, Thill, Marc, Blohmer, Jens-Uwe, Hackmann, John, Malter, Wolfram, Bekes, Inga, Friedrichs, Kay, Wojcinski, Sebastian, Joos, Sylvie, Paepke, Stefan, and Ditsch, Nina

Abstract

Objective: We evaluated the ability of minimally invasive, image-guided vacuum-assisted biopsy (VAB) to reliably diagnose a pathologic complete response in the breast (pCR-B). Summary Background Data: Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in up to 80% of women with breast cancer. In such cases, breast surgery, the gold standard for confirming pCR-B, may be considered overtreatment. Methods: This multicenter, prospective trial enrolled 452 women presenting with initial stage 1-3 breast cancer of all biological subtypes. Fifty-four women dropped out; 398 were included in the full analysis. All participants had an imaging-confirmed partial or complete response to NST and underwent study-specific image-guided VAB before guideline-adherent breast surgery. The primary endpoint was the false-negative rate (FNR) of VAB-confirmed pCR-B. Results: Image-guided VAB alone did not detect surgically confirmed residual tumor in 37 of 208 women [FNR, 17.8%; 95% confidence interval (CI), 12.8-23.7%]. Of these 37 women, 12 (32.4%) had residual DCIS only, 20 (54.1%) had minimal residual tumor (<5 mm), and 19 of 25 (76.0%) exhibited invasive cancer cellularity of <=10%. In 19 of the 37 cases (51.4%), the false-negative result was potentially avoidable. Exploratory analysis showed that performing VAB with the largest needle by volume (7-gauge) resulted in no false-negative results and that combining imaging and image-guided VAB into a single diagnostic test lowered the FNR to 6.2% (95% CI, 3.4%-10.5%). /p> Conclusions: Image-guided VAB missed residual disease more often than expected. Refinements in procedure and patient selection seem possible and necessary before omitting breast surgery. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer

Author

Gnjatic, Sacha, Cao, Yanran, Reichelt, Uta, Yekebas, Emre F., Nölker, Christina, Marx, Andreas H., Erbersdobler, Andreas, Nishikawa, Hiroyoshi, Hildebrandt, York, Bartels, Katrin, Horn, Christiane, Stahl, Tanja, Gout, Ivan, Filonenko, Valeriy, Ling, Khoon-Lin, Cerundolo, Vincenzo, Luetkens, Tim, Ritter, Gerd, Friedrichs, Kay, Leuwer, Rudolf, Hegewisch-Becker, Susanna, Izbicki, Jakob R., Bokemeyer, Carsten, Old, Lloyd J., and Atanackovic, Djordje

Published
2010
Full Text
View/download PDF

26. Ist eine Operation der Brust bei Komplettremission nach neoadjuvanter Chemotherapie des Mammakarzinoms notwendig?

Author

Richter, Hannah, Hennigs, André, Schäfgen, Benedikt, Hahn, Markus, Blohme, Jens-Uwe, Kümmel, Sherko, Kühn, Thorsten, Thill, Marc, Friedrichs, Kay, Sohn, Christof, Golatta, Michael, Heil, Jörg, Richter, Hannah, Hennigs, André, Schäfgen, Benedikt, Hahn, Markus, Blohme, Jens-Uwe, Kümmel, Sherko, Kühn, Thorsten, Thill, Marc, Friedrichs, Kay, Sohn, Christof, Golatta, Michael, and Heil, Jörg

Abstract

Die Wahrscheinlichkeit einer pathologischen Komplettremission (pCR) bei Brustkrebs nach neoadjuvanter Chemotherapie (NACT) nimmt zu; vor allem in den Subgruppen der tripel-negativen und HER-2-positiven Tumoren. Daher stellt sich die Frage, ob bei einer Komplettremission nach NACT eine operative Therapie der Brust notwendig ist, und ob es einen Vorteil für das onkologische Behandlungsergebnis hat, wenn kein Tumor mehr nachgewiesen werden kann. Ein Verzicht auf die Operation und gegebenenfalls auch auf die Radiotherapie ist jedoch nur auf der Basis einer verlässlichen pCR-Diagnose ohne Operation denkbar. Bildgebende Verfahren erreichen derzeit nicht die nötige Sensitivität und Spezifität, um die Diagnose einer pathologischen Komplettremission sicher zu stellen. Daher sind weitere Studien nötig, um herauszufinden, welche Methode die bestmögliche Evaluation des Tumoransprechens auf NACT erlaubt. Erste vielversprechende Ergebnisse zeigen sich in Studien zu bildgebungsgesteuerten, minimalinvasiven Biopsien nach NACT. Diese evaluieren die Möglichkeit einer pCR-Diagnose vor der Operation und könnten die Grundlage für weitere Studien zu einem möglichen Verzicht auf eine Operation in diesem ausgewählten Kollektiv sein., The likelihood of pathological complete remission (pCR) of breast cancer following neoadjuvant chemotherapy (NACT) is increasing; most of all in the triple negative and HER2 positive tumour subgroups. The question thus arises whether or not breast surgery is necessary when there is complete remission after NACT, and whether it provides any improvement of the oncological treatment result when tumour is no longer detectable. Avoiding surgery and possibly even radiotherapy would only be conceivable on the basis of a reliable diagnosis of pCR without operating. Current imaging does not achieve the necessary sensitivity and specificity to assure the diagnosis of pathological complete remission. Further studies are therefore required to determine which methods are best able to evaluate tumour response to NACT. Studies on image-guided, minimally invasive biopsies after NACT have delivered first promising results towards diagnosing pCR before surgery and could provide the basis for further studies on the possibility of avoiding surgery in this specific patient collective.

Published
2018

27. Is breast surgery necessary for breast carcinoma in complete remission following neoadjuvant chemotherapy?

Author

Richter, Hannah, Hennigs, André, Schäfgen, Benedikt, Hahn, Markus, Blohmer, Jens-Uwe, Kümmel, Sherko, Kühn, Thorsten, Thill, Marc, Friedrichs, Kay, Sohn, Christof, Golatta, Michael, Heil, Jörg, Richter, Hannah, Hennigs, André, Schäfgen, Benedikt, Hahn, Markus, Blohmer, Jens-Uwe, Kümmel, Sherko, Kühn, Thorsten, Thill, Marc, Friedrichs, Kay, Sohn, Christof, Golatta, Michael, and Heil, Jörg

Abstract

The likelihood of pathological complete remission (pCR) of breast cancer following neoadjuvant chemotherapy (NACT) is increasing; most of all in the triple negative and HER2 positive tumour subgroups. The question thus arises whether or not breast surgery is necessary when there is complete remission after NACT, and whether it provides any improvement of the oncological treatment result when tumour is no longer detectable. Avoiding surgery and possibly even radiotherapy would only be conceivable on the basis of a reliable diagnosis of pCR without operating. Current imaging does not achieve the necessary sensitivity and specificity to assure the diagnosis of pathological complete remission. Further studies are therefore required to determine which methods are best able to evaluate tumour response to NACT. Studies on image-guided, minimally invasive biopsies after NACT have delivered first promising results towards diagnosing pCR before surgery and could provide the basis for further studies on the possibility of avoiding surgery in this specific patient collective., Die Wahrscheinlichkeit einer pathologischen Komplettremission (pCR) bei Brustkrebs nach neoadjuvanter Chemotherapie (NACT) nimmt zu; vor allem in den Subgruppen der tripel-negativen und HER-2-positiven Tumoren. Daher stellt sich die Frage, ob bei einer Komplettremission nach NACT eine operative Therapie der Brust notwendig ist, und ob es einen Vorteil für das onkologische Behandlungsergebnis hat, wenn kein Tumor mehr nachgewiesen werden kann. Ein Verzicht auf die Operation und gegebenenfalls auch auf die Radiotherapie ist jedoch nur auf der Basis einer verlässlichen pCR-Diagnose ohne Operation denkbar. Bildgebende Verfahren erreichen derzeit nicht die nötige Sensitivität und Spezifität, um die Diagnose einer pathologischen Komplettremission sicher zu stellen. Daher sind weitere Studien nötig, um herauszufinden, welche Methode die bestmögliche Evaluation des Tumoransprechens auf NACT erlaubt. Erste vielversprechende Ergebnisse zeigen sich in Studien zu bildgebungsgesteuerten, minimalinvasiven Biopsien nach NACT. Diese evaluieren die Möglichkeit einer pCR-Diagnose vor der Operation und könnten die Grundlage für weitere Studien zu einem möglichen Verzicht auf eine Operation in diesem ausgewählten Kollektiv sein.

Published
2018

28. Desmoid Type Fibromatosis of the Breast: Ten-Year Institutional Results of Imaging, Histopathology, and Surgery.

Author

Lorenzen, Jörn, Cramer, Miriam, Buck, Nina, Friedrichs, Kay, Graubner, Kirsten, Lühr, Clara Sonja, Lindner, Christoph, and Niendorf, Axel

Subjects
ARCHIVES, MAMMOGRAMS, BREAST tumors, CANCER patients, HISTOLOGY, IMMUNOHISTOCHEMISTRY, MAGNETIC resonance imaging, STAINS & staining (Microscopy), DISEASE relapse, CONNECTIVE tissue tumors
Abstract

Background: Desmoid type fibromatoses has proven to be a diagnostic and therapeutic challenge, as they often appear primarily as a carcinoma of the breast with a high recurrence risk. Patients: A digital archive search was performed for the period from 2009 to the end of 2018. Inclusion criteria consisted of histological examination of at least the surgical specimen in the reference pathology department and at least a second opinion diagnosis in the reference radiology department. Results: A total of 14 women and 1 man underwent surgery on desmoid type fibromatosisof the breast. The average patient age was 49 years (range: 22–72 years). The mean tumor size was 2.2 cm (range: 0.8–4.2 cm). The tumor was detectable in mammography in 12 out of 13 patients and in all 15 patients in sonography. MRI was performed preoperatively in 6 patients; in all of the patients, the tumor was visualized with inhomogeneous contrast enhancement. In the imaging procedures, all desmoid type fibromatoses were classified as suspicious. Performing the core biopsy, preoperative histology confirmed desmoid fibromatosis in 12 out of 15 patients. Nuclear stain for ß-catenin was positive in 7 out of 10 patients.Negative staining was found for AE1/A3 in 10 out of 10 and CD34 in 12 out of 12 patients. In all of the patients, a single-stage operation without the detection of border-forming tumor margins was performed. The follow-up interval ranged from 16 to 96 months (mean: 44.86 months, median: 43 months). In this follow-up period, no patient was diagnosed with desmoid tumor recurrence. Conclusion: In imaging, desmoid type fibromatosis of the breast has typical malignancy-related criteria. Extensive preoperative diagnostics enable the planning of complete primary excision of the lesion and reduce the recurrence risk. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

29. Overexpression of p53 and prognosis in breast cancer

Author

Friedrichs, Kay, Gluba, Saskia, Eidtmann, Holger, and Jonat, Walter

Subjects
Breast cancer -- Prognosis, Tumor markers -- Measurement, Tumor suppressor genes -- Physiological aspects, Health
Abstract

Background. Assessment of prognostic markers in breast cancer independent of the axillary lymph node status is of major concern for the application of adjuvant treatment regimens. The current treatment decision is based mainly on the axillary lymph node status. Because of improved screening methods, the number and proportion of patients with node-negative disease are increasing, which warrants a search for reliable prognostic parameters. The application of tumor suppressor gene expression appears to be especially suited as a marker of the progress in malignant cellular dedifferentiation. Methods. Tumor tissues of 156 patients with primary invasive breast cancer were analyzed immunohistochemically for the presence of p53 protein in paraffin-embedded material. The reaction to monoclonal antibody PAb1801 yielded better results than did reactions to monoclonal antibody DO1 and polyclonal antibody CM-1. The significance of the immunohistochemical data was compared with a panel of established risk factors. Results. Nuclear accumulation of p53 protein proved to be an independent marker of dedifferentiation, regardless of the lymph node status. Tumors showing p53 immunoreactivity were significantly more often related with histological Grade 3 and the absence of steroid hormone receptors. Kaplan-Meier estimation and multivariate analysis of disease-free and overall survival rate corroborated the importance of p53 as a prognostic parameter. Conclusion. Overexpression of p53 protein emerged as a reliable and independent predictor for disease recurrence and reduced survival rates in patients with breast cancer.

Published
1993

30. Ist eine Operation der Brust bei Komplettremission nach neoadjuvanter Chemotherapie des Mammakarzinoms notwendig?

Author

Richter, Hannah, additional, Hennigs, André, additional, Schaefgen, Benedikt, additional, Hahn, Markus, additional, Blohmer, Jens, additional, Kümmel, Sherko, additional, Kühn, Thorsten, additional, Thill, Marc, additional, Friedrichs, Kay, additional, Sohn, Christof, additional, Golatta, Michael, additional, and Heil, Jörg, additional

Published
2018
Full Text
View/download PDF

31. Is Breast Surgery Necessary for Breast Carcinoma in Complete Remission Following Neoadjuvant Chemotherapy?

Author

Richter, Hannah, additional, Hennigs, André, additional, Schaefgen, Benedikt, additional, Hahn, Markus, additional, Blohmer, Jens, additional, Kümmel, Sherko, additional, Kühn, Thorsten, additional, Thill, Marc, additional, Friedrichs, Kay, additional, Sohn, Christof, additional, Golatta, Michael, additional, and Heil, Jörg, additional

Published
2018
Full Text
View/download PDF

32. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Author

Gligorov, J., primary, Ataseven, B., additional, Verrill, M., additional, De Laurentiis, M., additional, Jung, K.H., additional, Azim, H.A., additional, Al-Sakaff, N., additional, Lauer, S., additional, Shing, M., additional, Pivot, X., additional, Koroveshi, Dhurata, additional, Bouzid, Kamel, additional, Casalnuovo, Monica, additional, Cascallar, Diana, additional, Korbenfeld, Ernesto Pablo, additional, Bastick, Patricia, additional, Beith, Jane, additional, Colosimo, Maree, additional, Friedlander, Michael, additional, Ganju, Vinod, additional, Green, Michael, additional, Patterson, Kevin, additional, Redfern, Andrew, additional, Richardson, Gary, additional, Ceric, Timur, additional, Gordana, Kecman, additional, Beato, Carlos Augusto, additional, Ferrari, Marcela, additional, Hegg, Roberto, additional, Helena, Vanessa, additional, Ismael, Gustavo Fernando, additional, Lessa, Alvaro Edson, additional, Mano, Max, additional, Morelle, Alessandra, additional, Nogueira, Jose Alberto, additional, Timcheva, Konstanta, additional, Tomova, Antoaneta, additional, Tsakova, Maya, additional, Zlatareva-Petrova, Ani, additional, Asselah, Jamil, additional, Assi, Hazem, additional, Brezden-Masley, Christine, additional, Chia, Stephen, additional, Freedman, Ori, additional, Harb, Mohammed, additional, Joy, Anil Abraham, additional, Kulkarni, Swati, additional, Prady, Catherine, additional, Gaete, Alejandro Andres Acevedo, additional, Matamala, Luis, additional, Torres, Roberto, additional, Yanez, Eduardo, additional, Franco, Sandra, additional, Urrego, Marcela, additional, Gugić, Damir, additional, Vrbanec, Damir, additional, Melichar, Bohuslav, additional, Prausová, Jana, additional, Vyzula, Rostislav, additional, Pilarte, Rafael Gutierrez, additional, León, María Isabel, additional, Muñoz, Rene, additional, Ramos, Glenda, additional, Azeem, Hamdy Abdel, additional, Aziz, Amr Abdel, additional, El Zawahry, Heba, additional, Osegueda, Finlander Rosales, additional, Alexandre, Jerome, additional, Artignan, Xavier, additional, Barletta, Hugues, additional, Beguier, Emmanuel, additional, Berdah, Jean-François, additional, Marty, Chantal Bernard, additional, Bollet, Marc, additional, Bourgeois, Hugues, additional, Bressac, Claude, additional, Burki, Franck, additional, Campone, Mario, additional, Coeffic, David, additional, Cojocarasu, Oana Zveltlana, additional, Dagada, Corinne, additional, Dalenc, Florence, additional, Del Piano, Francesco, additional, Desauw, Christophe, additional, Desmoulins, Isabelle, additional, Dohollou, Nadine, additional, Egreteau, Joelle, additional, Ferrero, Jean-Marc, additional, Foa, Cyril, additional, Garidi, Reda, additional, Gasnault, Laurent, additional, Gligorov, Joseph, additional, Guardiola, Emmanuel, additional, Hamizi, Salima, additional, Jarcau, Rosana, additional, Jacquin, Jean-Philippe, additional, Jaubert, Dominique, additional, Jolimoy, Geneviève, additional, Mineur, Hortense Laharie, additional, Largillier, Remy, additional, Leduc, Bernard, additional, Martin, Philippe, additional, Melis, Adrien, additional, Monge, Jeremy, additional, Moullet, Isabelle, additional, Mousseau, Mireille, additional, Nguyen, Suzanne, additional, Orfeuvre, Hubert, additional, Petit, Thierry, additional, Pivot, Xavier, additional, Priou, Frank, additional, Bach, Isabelle Sillet, additional, Simon, Helene, additional, Stefani, Laetitia, additional, Uwer, Lionel, additional, Youssef, Ali, additional, Aktas, Bahriye, additional, von der Assen, Albert, additional, Augustin, Doris, additional, Balser, Christina, additional, Bauer, Lelia-Eveline, additional, Bechtner, Christina, additional, Beyer, Greta, additional, Brucker, Cosima, additional, Bückner, Ute, additional, Busch, Steffi, additional, Christensen, Bernd, additional, Deryal, Mustafa, additional, Farrokh, Andre, additional, Faust, Elke, additional, Friedrichs, Kay, additional, Graf, Heiko, additional, Griesshammer, Martin, additional, Grischke, Eva-Maria, additional, Hänle, Claudia, additional, Heider, Andrea, additional, Henschen, Stephan, additional, Hesse, Tobias, additional, Jackisch, Christian, additional, Kisro, Jens, additional, Köhler, Andreas, additional, Kuemmel, Sherko, additional, Lampe, Dieter, additional, Lantzsch, Tilmann, additional, Latos, Kunibert, additional, Lex, Benno, additional, Liedtke, Cornelia, additional, Luedders, Doerte, additional, Maintz, Christoph, additional, Müller, Volkmar, additional, Overkamp, Friedrich, additional, Park-Simon, Tjoung-won, additional, Paul, Marion, additional, Prechtl, Anita, additional, Ringsdorf, Uta, additional, Runnebaum, Ingo, additional, Ruth, Sylvia, additional, Salat, Christoph, additional, Scheffen, Iris, additional, Schilling, Jörg, additional, Schmatloch, Sabine, additional, Schmidt, Marcus, additional, Schneeweiss, Andreas, additional, Schrader, Iris, additional, Seipelt, Gernot, additional, Simon, Elke, additional, Stefek, Andrea, additional, Stickeler, Elmar, additional, Thill, Marc, additional, Tio, Joke, additional, Tuczek, Anna, additional, Warm, Mathias, additional, Weigel, Michael, additional, Wischnik, Arthur, additional, Wojcinski, Sebastian, additional, Ziegler-Löhr, Katja, additional, Aravantinos, Gerasimos, additional, Ardavanis, Alexandros, additional, Fountzilas, George, additional, Gogas, Helen, additional, Kakolyris, Stylianos, additional, Mavroudis, Dimitris, additional, Papadimitriou, Christos, additional, Papandreou, Christos, additional, Papazisis, Konstantinos, additional, Castro, Hugo, additional, Hernandez-Monroy, Cesar Estuardo, additional, Ngan, Roger, additional, Yeo, Winnie, additional, Bittner, Nora, additional, Boer, Katalin, additional, Csejtei, Andras, additional, Horvath, Zsolt, additional, Kocsis, Judit, additional, Mangel, László Csaba, additional, Mezei, Klara, additional, Nagy, Zsuzsanna, additional, Szanto, Janos, additional, Atmakusuma, Djumhana, additional, Fadjari, Heri, additional, Kurnianda, Djohan, additional, Prayogo, Nugroho, additional, Tanggo, Eddie Herman, additional, Coate, Linda, additional, Hennessy, Bryan, additional, Kelly, Cathy, additional, Martin, Michael, additional, Nasim, Saira, additional, O'Connor, Miriam, additional, Aieta, Michele, additional, Allegrini, Giacomo, additional, Amadori, Dino, additional, Bidoli, Paolo, additional, Biti, Giampaolo, additional, Bordonaro, Roberto, additional, Bottini, Alberto, additional, Carterni, Giacomo, additional, Cavanna, Luigi, additional, Cazzaniga, Marina, additional, Cognetti, Francesco, additional, Contu, Antonio, additional, Cruciani, Giorgio, additional, Donadio, Michela, additional, Falcone, Alfredo, additional, Farci, Daniele, additional, Forcignanò, R. Chiara, additional, Frassoldati, Antonio, additional, Gaion, Fernando, additional, Gamucci, Teresa, additional, Giotta, Francesco, additional, de Laurentiis, Michele, additional, Livi, Lorenzo, additional, Lorusso, Vito, additional, Maiello, Evaristo, additional, Marchetti, Paolo, additional, Mariani, Gabriella, additional, Mion, Marta, additional, Moscetti, Luca, additional, Musolino, Antonino, additional, Pazzola, Antonio, additional, Pedrazzoli, Paolo, additional, Pigi, Andrea, additional, de Placido, Sabino, additional, Caremoli, Elena Rota, additional, Santoro, Armando, additional, Tienghi, Amelia, additional, Ahn, Jin-Seok, additional, Jung, Kyung Hae, additional, Lee, Keun Seok, additional, Lee, Soo Hyeon, additional, Seo, Jae Hong, additional, Sohn, Joo-Hyuk, additional, Cesas, Alvydas, additional, Juozaityte, Elona, additional, Cheah, Nellie Lay Chin, additional, Chong, Flora Li Tze, additional, Devi, Beena C.R., additional, Phua, Vincent, additional, Teoh, Darren, additional, Ching, Lee Wei, additional, Yusof, Mastura, additional, Corona, Jorge, additional, Dominguez, Adriana, additional, Mendoza, René Lazaro González, additional, Hernandez, Carlos Alberto, additional, Ramiro, Alejandro Juarez, additional, Santos, Juan Matos, additional, Espinosa, Paola Morales, additional, Villarreal Garza, Cynthia Mayte, additional, Errihani, Hassan, additional, Bakker, Sandra, additional, van den Berkmortel, Franchette, additional, Blaisse, R.J.B., additional, Huinink, Daan ten Bokkel, additional, van den Bosch, J., additional, Braun, J.J., additional, Dercksen, M.W., additional, Droogendijk, Helga, additional, Erdkamp, Frans, additional, Haringhuizen, Annebeth, additional, de Jongh, F.E., additional, Kok, T.C., additional, Los, Maartje, additional, Madretsma, Stanley, additional, Terwogt, Jetske M. Meerum, additional, van der Padt, Annemieke, additional, van Rossum-Schornagel, Quirine Clementine, additional, Smilde, T.J., additional, de Valk, Bart, additional, van der Velden, Annette, additional, van Warmerdam, Laurence, additional, van de Wouw, A.J., additional, North, Richard, additional, Kersten, Christian, additional, Mjaaland, Ingvild, additional, Wist, Erik, additional, Aziz, Zeba, additional, Masood, Nehal, additional, Rashid, Kamran, additional, Shah, Mazhar, additional, Alcedo, Juan Carlos, additional, Aleman, Diana, additional, Neciosup, Silvia, additional, Reategui, Rocio, additional, Valdiviezo, Natalia, additional, Vera, Luis, additional, Fernando, Gracieux, additional, Roque, Fernando, additional, Strebel, Heinrik Martin, additional, Krzemieniecki, Krzysztof, additional, Litwiniuk, Maria, additional, Mruk, Andrzej, additional, Pienkowski, Tadeusz, additional, Sawrycki, Piotr, additional, Slomian, Grzegorz, additional, Tomczak, Piotr, additional, Afonso, Noemia, additional, Cardoso, Fátima, additional, Damasceno, Margarida, additional, Nave, Monica, additional, Badulescu, Florinel, additional, Ciule, Larisa, additional, Curescu, Stefan, additional, Eniu, Alexandru, additional, Filip, Dumitru, additional, Grecea, Daniela, additional, Jinga, Dan-Corneliu, additional, Lungulescu, Dan, additional, Oprean, Cristina Marinela, additional, Stanculeanu, Dana Lucia, additional, Turdean, Maria, additional, Dvornichenko, Viktoria, additional, Emelyanov, Sergey, additional, Lichinitser, Mikhail, additional, Manikhas, Alexey, additional, Sakaeva, Dina, additional, Shirinkin, Vadim, additional, Stroyakovskiy, Daniil, additional, Abulkhair, Omalkhair, additional, Zekri, Jamal, additional, Filipovic, Sladjana, additional, Kovcin, Vladimir, additional, Nedovic, Jasmina, additional, Pesic, Jasna, additional, Vasovic, Suzana, additional, Ng, Raymond, additional, Bystricky, Branislav, additional, Leskova, Jaroslava, additional, Mardiak, Jozef, additional, Mišurová, Etela, additional, Wagnerova, Maria, additional, Takač, Iztok, additional, Demetriou, Georgia Savva, additional, Dreosti, Lydia, additional, Govender, Poovandren, additional, Jordaan, Johannes Petrus, additional, Veersamy, Petrosian, additional, Romero, Jose Luis Alonso, additional, Lopez, Norberto Batista, additional, Arias, Carmen Cañabate, additional, Chacon, Jose, additional, Aramburo, Antonio Fernandez, additional, Morales, Luis Antonio Fernandez, additional, Garcia, Mirta, additional, Estevez, Laura Garcia, additional, Garcia-Palomo Perez, Andres, additional, Garcia Saenz, Jose Angel, additional, Garcia Sanchis, Laura, additional, Cubells, Laia Garrigos, additional, Cortijo, Lucia Gonzalez, additional, Santiago, Santiago Gonzalez, additional, De Aranguiz, Blanca Hernando Fernandez, additional, Mañas, José Juan Illarramendi, additional, Gallego, Pedro Jimenez, additional, Cussac, Antonio Llombart, additional, Ferrandiz, Cristina Llorca, additional, Garrido, Maria Lomas, additional, Alvarez, Pilar Lopez, additional, Vega, Jose Manuel Lopez, additional, Del Prado, Purificacion Martinez, additional, Jañez, Noelia Martinez, additional, Murillo, Serafin Morales, additional, Rosales, Adolfo Murias, additional, Jaso, Laura Murillo, additional, Fernandez, Ignacio Pelaez, additional, Martorell, Antonia Perello, additional, Carrion, Ramon Perez, additional, Simon, Sonia Pernas, additional, Alcibar, Arrate Plazaola, additional, Lorenzo, Jose Ponce, additional, Garcia, Vanesa Quiroga, additional, Asensio, Teresa Ramon y Cajal, additional, Maicas, Maria Dolores Torregrosa, additional, Villanueva Silva, Maria Jose, additional, Killander, Fredrika, additional, Svensson, Jan Henry, additional, Fehr, Mathias, additional, Hauser, Nik, additional, Müller, Andreas, additional, Pagani, Olivia, additional, Passmann-Kegel, Heike, additional, Popescu, Razvan, additional, Rabaglio, Manuela, additional, Rauch, Daniel, additional, Schlatter, Christina, additional, Zaman, Khalil, additional, Chang, Tsai-Wang, additional, Huang, Chiun-Sheng, additional, Wang, Hwei-Chung, additional, Yu, Jyh-Cherng, additional, Bandidwattanawong, Chanyoot, additional, Maneechavakajorn, Jedzada, additional, Seetalarom, Kasan, additional, Dejthevaporn, Thitiya (Sirisinha), additional, Somwangprasert, Areewan, additional, Vongsaisuwon, Mawin, additional, Akbulut, Hakan, additional, Altundag, Kadri, additional, Arican, Ali, additional, Bozcuk, Hakan, additional, Eralp, Yesim, additional, Idris, Mohamed, additional, Isikdogan, Abdurrahman, additional, Senol, Coskun Hasan, additional, Sevinc, Alper, additional, Uygun, Kazim, additional, Yucel, Eftal, additional, Yucel, Idris, additional, Yumuk, Fulden, additional, Shparyk, Yaroslav, additional, Voitko, Nataliia, additional, Jaloudi, Mohammed, additional, Adams, Jocelyn, additional, Agrawal, Rajiv, additional, Ahmed, Samreen, additional, Alhasso, Abdulla, additional, Allerton, Rozenn, additional, Anwar, Suhail, additional, Archer, Caroline, additional, Ashford, Richard, additional, Barraclough, Lisa, additional, Bertelli, Gianfilippo, additional, Bishop, Jill, additional, Branson, Tony, additional, Butt, Mohammed, additional, Chakrabarti, Amit, additional, Chakraborti, Prabir, additional, Churn, Mark, additional, Crowley, Clare, additional, Davis, Ruth, additional, Dhadda, Amandeep, additional, Eldeeb, Hany, additional, Fraser, Judith, additional, Hall, Julia, additional, Hickish, Tamas, additional, Hogg, Martin, additional, Howe, Theresa, additional, Joffe, Jonathan, additional, Kelleher, Muireann, additional, Kelly, Stephen, additional, Kendall, Anne, additional, Kristeleit, Hartmut, additional, Lumsden, Graeme, additional, Macmillan, Craig, additional, MacPherson, Iain, additional, Malik, Zafar, additional, Mithal, Natasha, additional, Neal, Anthony, additional, Panwar, Udaiveer, additional, Proctor, Andrew, additional, Proctor, Steven John, additional, Raj, Sanjay, additional, Rehman, Shazza, additional, Sandri, Ines, additional, Scatchard, Kate, additional, Sherwin, Elizabeth, additional, Sims, Eliot, additional, Singer, Julian, additional, Smith, Sarah, additional, Tahir, Saad, additional, Taylor, Wendy, additional, Tsalic, Medy, additional, Verrill, Mark, additional, Wardley, Andrew, additional, Waters, Simon, additional, Wheatley, Duncan, additional, Wright, Kathryn, additional, Yuille, Frances, additional, Alonso, Isabel, additional, Artagaveytia, Nora, additional, Rodriguez, Robinson, additional, Arbona, Esther, additional, Garcia, Yuraima, additional, Lion, Lorena, additional, Marcano, Dalila, additional, and Van Thuan, Tran, additional

Published
2017
Full Text
View/download PDF

35. Vom Intelligent Building zur Telekooperation

Author

Friedrichs, Kay and Sieber, Heinz

Subjects
Bürohaus, Telearbeit, Telekooperation, ddc:720, Architektur
Abstract

World-wide there is a great deal of movement on the market for office buildings. Since the middle of the 1990's, the steady demand-led market for office space has developed in many places to a market for suppliers. A deregulation process has been taking place in Germany for several years in the organisational structure of larger industrial enterprises, supra-regional services and public authorities. A project, or department oriented budgeting of all resources is part of this reorganisation. Above all the optimisation of the utilisation of the working area becomes the centre of a dynamic organisation of the work, as here a considerable potential for improvement can be seen. Assuming adequate space qualities, this can lead to a higher working quality. Information technology is improving software tools and the technical infrastructure for telephone networks with high bandwidths. These and other innovations bring tele-working into the area of a realistic possibility, where teamwork can be organised and carried out through a computer network. A long-proclaimed work paradigm only possible in theory can now become true: 'the office is where you are'. In this way, the requirements of offices, their technical infrastructure and their management models are changing. Harmonised with the working processes of a modern information society, the intelligent planning of flexibly usable buildings, their industrial production, technical adaptability, lifecycle and management processes will become the decisive question for building concepts for the future.

Published
2001

37. KoopBuilding

Author

Friedrichs, Kay, Hovestadt, Ludger, and Hovestadt, Volkmar

Subjects
ddc:690, Buildings
Published
1997
Full Text
View/download PDF

38. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

Author

Durbecq, Virginie, Paesmans, Marianne, Cardoso, Fatima, Desmedt, Christine, Di Leo, Angelo, Chan, Stephen, Friedrichs, Kay, Pinter, Tamas, Van Belle, Simon, Murray, Elizabeth, Bodrogi, István, Walpole, Euan, Lesperance, Bernard, Korec, Stefan, Crown, John, Simmonds, Peter, Perren, Thimothy J., Leroy, Jean-Yves, Rouas, Ghizlane, Sotiriou, Christos, Piccart-Gebhart, Martine, Larsimont, Denis, Durbecq, Virginie, Paesmans, Marianne, Cardoso, Fatima, Desmedt, Christine, Di Leo, Angelo, Chan, Stephen, Friedrichs, Kay, Pinter, Tamas, Van Belle, Simon, Murray, Elizabeth, Bodrogi, István, Walpole, Euan, Lesperance, Bernard, Korec, Stefan, Crown, John, Simmonds, Peter, Perren, Thimothy J., Leroy, Jean-Yves, Rouas, Ghizlane, Sotiriou, Christos, Piccart-Gebhart, Martine, and Larsimont, Denis

Abstract

Purpose: The predictive value of topoisomerase-IIα (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel. Experimental design: Primary tumor samples from patients enrolled in a randomized, phase III clinical trial comparing single-agent doxorubicin (75 mg/m2 q3wks) with docetaxel (100 mg/m2 q3wks) were collected and topo-II status was evaluated by immunohistochemistry (clone KiS1). Results: Topo-II status was evaluated in 108 samples, 55 (51%) in the doxorubicin arm and 53 (49%) in the docetaxel arm. An increment of 10% in cells expressing topo-II is associated with a statistically significant odds ratio (OR; 95% confidence interval) of 1.09 (1.03 - 1.15; P = 0.002) for overall response to doxorubicin versus 1.002 (0.94-1.07; P = 0.95) in the docetaxel arm. With increasing topo-II, the favorable OR for overall response to docetaxel compared with doxorubicin decreases to become not significant in patients with topo-II tumor content > 10%. In a multivariate analysis, (a) HER-2 status seems positively correlated with overall response to chemotherapy (OR, 2.34; 95% confidence interval, 0.87-6.27; P = 0.09). (b) Overall response to doxorubicin is significantly lower than overall response to docetaxel (OR, 0.17; 95% confidence interval, 0.04-0.64; P = 0.009) but with a significant interaction term for doxorubicin-treated patients with topo-II tumor content > 10% (OR, 8.31; 95% confidence interval, 1.86-37.03; P = 0.05). Conclusions: (a) Topo-II overexpression confers a higher probability of response in the doxorubicin arm only. (b) Despite being a small retrospective study, this study is in line with previously reported studies and the hypotheses raised are now being tested in a prospective neoadjuvant trial. Copyright © 2004 American Association for Cancer Research., Clinical Trial, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published

Published
2004

39. p-53 gene mutations as a predictive marker in advanced breast cancer patients randomly treated either with doxorubicin or with docetaxel

Author

Desmedt, Christine, Tanner, M, Di Leo, Angelo, Paesmans, Marianne, Cardoso, Fatima, Durbecq, Virginie, Chan, S, Friedrichs, Kay, Van Belle, S., Leroy, Jean-Yves, Sotiriou, Christos, Larsimont, Denis, Piccart-Gebhart, Martine, Isola, Jorma, Desmedt, Christine, Tanner, M, Di Leo, Angelo, Paesmans, Marianne, Cardoso, Fatima, Durbecq, Virginie, Chan, S, Friedrichs, Kay, Van Belle, S., Leroy, Jean-Yves, Sotiriou, Christos, Larsimont, Denis, Piccart-Gebhart, Martine, and Isola, Jorma

Abstract

1034, info:eu-repo/semantics/published

Published
2004

40. Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated with single-agent doxorubicin or single-agent docetaxel.

Author

Desmedt, Christine, Durbecq, Virginie, Paesmans, Marianne, Sotiriou, Christos, Leroy, Jean-Yves, Rouas, Ghizlane, Chan, S, Friedrichs, Kay, Pinter, Tamas, Van Belle, S., Murray, Elizabeth, Perren, Thimothy J., Olsen, S., Di Leo, Angelo, Cardoso, Fatima, Piccart-Gebhart, Martine, Larsimont, Denis, Desmedt, Christine, Durbecq, Virginie, Paesmans, Marianne, Sotiriou, Christos, Leroy, Jean-Yves, Rouas, Ghizlane, Chan, S, Friedrichs, Kay, Pinter, Tamas, Van Belle, S., Murray, Elizabeth, Perren, Thimothy J., Olsen, S., Di Leo, Angelo, Cardoso, Fatima, Piccart-Gebhart, Martine, and Larsimont, Denis

Abstract

info:eu-repo/semantics/published

Published
2004

41. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

Author

Di Leo, Angelo, Chan, S, Paesmans, Marianne, Friedrichs, Kay, Pinter, Tamas, Cocquyt, Veronique, Murray, Elizabeth, Bodrogi, István, Walpole, Euan, Lesperance, Bernard, Korec, Stefan, Crown, John, Simmonds, Peter, Von Minckwitz, G, Leroy, Jean-Yves, Durbecq, Virginie, Isola, Jorma, Aapro, Matti, Piccart-Gebhart, Martine, Larsimont, Denis, Di Leo, Angelo, Chan, S, Paesmans, Marianne, Friedrichs, Kay, Pinter, Tamas, Cocquyt, Veronique, Murray, Elizabeth, Bodrogi, István, Walpole, Euan, Lesperance, Bernard, Korec, Stefan, Crown, John, Simmonds, Peter, Von Minckwitz, G, Leroy, Jean-Yves, Durbecq, Virginie, Isola, Jorma, Aapro, Matti, Piccart-Gebhart, Martine, and Larsimont, Denis

Abstract

PURPOSE: To evaluate the predictive value of HER-2 in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin (A) or with single-agent docetaxel (T). EXPERIMENTAL DESIGN: Patients from this study participated in a phase III clinical trial in which doxorubicin or docetaxel was administered for advanced disease. HER-2 was evaluated by IHC. In all positive cases, FISH was used to confirm the HER-2 positive status. The different cohorts of patients identified by HER-2 were examined to assess a possible relationship between HER-2 status and treatment effect. RESULTS: Tumor samples were available for 176 of the 326 patients entered in the clinical trial (54%). HER-2 positivity was observed in 20% of the study population. A statistically significant interaction was found between response rates to the study drugs and HER-2 status, with HER-2 positive patients deriving the highest benefit from the use of T (odds ratio for HER-2 positive patients treated with T = 3.12 (95% CI 1.11-8.80), p = 0.03). The interaction between HER-2 and response rates to A and T was also confirmed by a multivariate analysis. No statistically significant interaction was found between HER-2 and drugs efficacy evaluated in terms of time to progression and overall survival, although in the HER-2 negative cohort A was at least as effective as T in term of overall survival. CONCLUSIONS: These results suggest that in HER-2 positive breast cancer patients docetaxel might be more active than doxorubicin, while in HER-2 negative patients doxorubicin might be at least as effective as docetaxel. Although the present results cannot have an impact on current practice, they allow us to formulate the hypothesis that HER-2 positive breast cancer is a heterogeneous disease with regard to sensitivity to anthracyclines and taxanes, and that this might be dependent upon other molecular markers including the p-53 and topoisomerase II alpha genes. This hypothesis is currentl, Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published

Published
2004

42. CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer

Author

Marmé, Frederik, primary, Werft, Wiebke, additional, Walter, Anne, additional, Keller, Sascha, additional, Wang, Xiaoli, additional, Benner, Axel, additional, Burwinkel, Barbara, additional, Sinn, Peter, additional, Hug, Sarah, additional, Sohn, Christof, additional, Bretz, Niko, additional, Moldenhauer, Gerhard, additional, Rupp, Christian, additional, Rupp, Anne-Kathleen, additional, Biakhov, Mikhail Y., additional, Bottini, Alberto, additional, Friedrichs, Kay, additional, Khailenko, V. A., additional, Manikhas, Georgiy M., additional, Ruiz, Amparo, additional, Sánchez-Rovira, Pedro, additional, Santoro, Armando, additional, Segui, Miguel A., additional, Villena, Carlos, additional, Lichter, Peter, additional, Kristiansen, Glen, additional, Altevogt, Peter, additional, and Schneeweiss, Andreas, additional

Published
2011
Full Text
View/download PDF

43. PPFIA1 and CCND1 are frequently coamplified in breast cancer

Author

Dancau, Ana‐Maria, primary, Wuth, Laura, additional, Waschow, Marcel, additional, Holst, Frederik, additional, Krohn, Antje, additional, Choschzick, Matthias, additional, Terracciano, Luigi, additional, Politis, Sotirios, additional, Kurtz, Stefan, additional, Lebeau, Annette, additional, Friedrichs, Kay, additional, Wencke, Katharina, additional, Monni, Outi, additional, and Simon, Ronald, additional

Published
2009
Full Text
View/download PDF

44. AGO Recommendations for the Diagnosis and Therapy of Breast Cancer

Author

Thomssen, Christoph, primary, Bauerfeind, Ingo, additional, Bischoff, Joachim, additional, Blohmer, Jens Uwe, additional, Brunnert, Klaus, additional, Costa, Serban D., additional, Dall, Peter, additional, Diel, Ingo J., additional, Fersis, Nikos, additional, Friedrich, Michael, additional, Friedrichs, Kay, additional, Gerber, Bernd, additional, Göhring, Uwe-Jochen, additional, Hanf, Volker, additional, Harbeck, Nadia, additional, Huober, Jens, additional, Jackisch, Christian, additional, Janni, Wolfgang, additional, Jonat, Walter, additional, Kaufmann, Manfred, additional, Lück, Hans-Joachim, additional, Maass, Nicolai, additional, Möbus, Volker, additional, Nitz, Ulrike, additional, Oberhoff, Carsten, additional, Rezai, Mahdi, additional, Schaller, Gerhard, additional, Scharl, Anton, additional, Schmutzler, Rita, additional, Schneeweiss, Andreas, additional, Schreer, Ingrid, additional, Kreipe, H., additional, Sinn, Peter, additional, Solomayer, Erich F., additional, Souchon, Rainer, additional, Stickeler, Elmar, additional, Thomssen, Christoph, additional, Untch, Michael, additional, and von Minckwitz, Gunter, additional

Published
2007
Full Text
View/download PDF

45. Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

Author

Durbecq, Virginie, primary, Paesmans, Marianne, additional, Cardoso, Fatima, additional, Desmedt, Christine, additional, Di Leo, Angelo, additional, Chan, Stephen, additional, Friedrichs, Kay, additional, Pinter, Tamas, additional, Van Belle, Simon, additional, Murray, Elizabeth, additional, Bodrogi, István, additional, Walpole, Euan, additional, Lesperance, Bernard, additional, Korec, Stefan, additional, Crown, John, additional, Simmonds, Peter, additional, Perren, Thimothy J., additional, Leroy, Jean-Yves, additional, Rouas, Ghizlane, additional, Sotiriou, Christos, additional, Piccart, Martine, additional, and Larsimont, Denis, additional

Published
2004
Full Text
View/download PDF

46. Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

Author

Chan, Stephen, primary, Friedrichs, Kay, additional, Noel, Daniel, additional, Pintér, Tamàs, additional, Van Belle, Simon, additional, Vorobiof, Daniel, additional, Duarte, Ricardo, additional, Gil Gil, Miguel, additional, Bodrogi, Istvan, additional, Murray, Elizabeth, additional, Yelle, Louise, additional, von Minckwitz, Gunter, additional, Korec, Stefan, additional, Simmonds, Peter, additional, Buzzi, Franco, additional, González Mancha, Rosario, additional, Richardson, Gary, additional, Walpole, Euan, additional, Ronzoni, Monica, additional, Murawsky, Michael, additional, Alakl, May, additional, Riva, Alessandro, additional, and Crown, John, additional

Published
1999
Full Text
View/download PDF

49. MarginProbe® – Final results of the German post-market study in breast conserving surgery of ductal carcinoma in situ.

Author

Thill, Marc, Dittmer, Christine, Baumann, Kristin, Friedrichs, Kay, and Blohmer, Jens-Uwe

Subjects
BREAST surgery, DUCTAL carcinoma, SURGICAL excision, BREAST cancer patients, INTRAOPERATIVE care, ADJUVANT treatment of cancer
Abstract

Abstract: The goal in breast conserving surgery (BCS) of ductal carcinoma in situ (DCIS) is removal of the tumor with a clear surgical margin. However, re-excision rates are regrettably high. To date, there are no adequate procedures for intraoperative margin assessment of DCIS. A multicenter, single arm study was conducted to evaluate the benefit of a novel device (MarginProbe®) in intraoperative margin assessment during BCS of DCIS, the associated reduction of re-excisions and the cosmetic outcome of the treated patients. We present results of 42 patients enrolled in 3 German institutions. The device was used as an adjunctive tool to standard of care. The device use was associated with a reduction in re-excision rates by 56%, from 39% to 17% (p = 0.018). [Copyright &y& Elsevier]

Published
2014
Full Text
View/download PDF

50. Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.

Author

Bendrat K, Fritz P, Müller S, Brockmöller S, Debus A, Friedrichs K, Lindner C, Brinkmann F, Heidemann E, and Niendorf A

Subjects
Aged, Biomarkers, Tumor genetics, Breast Neoplasms pathology, Estrogen Receptor alpha genetics, Estrogens genetics, Female, Gene Expression Regulation, Neoplastic, Humans, Kaplan-Meier Estimate, Middle Aged, Prognosis, Receptors, Progesterone genetics, Risk Assessment, Biomarkers, Tumor biosynthesis, Breast Neoplasms diagnosis, Breast Neoplasms genetics, Estrogen Receptor alpha biosynthesis, Receptors, Progesterone biosynthesis
Abstract

Background: The receptors for estrogen (ESR1) and progesterone (PGR) are both part of the same signaling pathway and routinely used for breast cancer stratification. We tested the hypothesis if a coordinated analysis could add extra information for prognostic stratification., Materials and Methods: ESR1 and PGR gene expression was first investigated by quantitative reverse transcription polymerase chain reaction in fresh-frozen invasive ductal breast cancer samples (Hamburg collective, case-control, n=317). Our results were then tested using two datasets generated by different technical approaches: i) a public DNA-chip data set (GSE3494, n=251) and ii) semiquantitative protein expression data based on immunohistochemistry (Stuttgart collective, n=18,528)., Results: The PGR/ESR1 gene-expression ratio was a prognostic indicator in those with ESR1/PGR-positive breast cancer (Hamburg collective), with a high PGR/ESR1 expression ratio indicating a favorable outcome. In all three collectives, the PGR/ESR1 mRNA ratio or its protein equivalent was a univariate prognostic factor and also a multivariate prognostic factor in the Hamburg and Stuttgart collectives., Conclusion: Calculation of the PGR/ESR1 gene-expression ratio and its immunohistochemical surrogate could be a useful and simple addition to routine breast cancer diagnostics. A high PGR/ESR1 ratio could be indicative of a favorable clinical outcome., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results